SOLV vs. RMD, WST, BAX, PODD, SWAV, TFX, GMED, PEN, GKOS, and MMSI
Should you be buying Solventum stock or one of its competitors? The main competitors of Solventum include ResMed (RMD), West Pharmaceutical Services (WST), Baxter International (BAX), Insulet (PODD), Shockwave Medical (SWAV), Teleflex (TFX), Globus Medical (GMED), Penumbra (PEN), Glaukos (GKOS), and Merit Medical Systems (MMSI). These companies are all part of the "surgical & medical instruments" industry.
ResMed (NYSE:RMD) and Solventum (NYSE:SOLV) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment, institutional ownership and community ranking.
In the previous week, ResMed had 8 more articles in the media than Solventum. MarketBeat recorded 11 mentions for ResMed and 3 mentions for Solventum. Solventum's average media sentiment score of 0.90 beat ResMed's score of 0.50 indicating that ResMed is being referred to more favorably in the media.
ResMed received 415 more outperform votes than Solventum when rated by MarketBeat users. Likewise, 52.93% of users gave ResMed an outperform vote while only 0.00% of users gave Solventum an outperform vote.
ResMed presently has a consensus target price of $202.80, suggesting a potential downside of 1.71%. Solventum has a consensus target price of $65.75, suggesting a potential upside of 10.80%. Given ResMed's higher probable upside, analysts plainly believe Solventum is more favorable than ResMed.
ResMed has a net margin of 20.91% compared to ResMed's net margin of 0.00%. Solventum's return on equity of 24.43% beat ResMed's return on equity.
ResMed has higher revenue and earnings than Solventum.
55.0% of ResMed shares are held by institutional investors. 1.2% of ResMed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
ResMed beats Solventum on 12 of the 13 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding SOLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Solventum Competitors List
Related Companies and Tools
